Emma Guttman-Yassky, MD: Evaluating Long-term Efficacy of Upadacitinib in Patients with Atopic Dermatitis

Andrew Mastro discusses the impact chronic hand eczema has on patients’ quality of life and provides an update on emerging treatments for the disease, such

Andrew Mastro discusses various challenges of treating AD in the head-and-neck area, emphasizing the importance in choosing a treatment armed with rapidity, power, and a

Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients

Melodie Young discusses managing treatment for younger children with atopic dermatitis, emphasizing the importance of focusing on potential and probable side effects with their caregivers.

Melodie Young discusses the logistics of gaining access to newer medications through speciality pharmacies for patients with atopic dermatitis.

Andrea Nguyen, PA-C, MS, discusses how the internet and social media has contributed to more in-depth discussion with her patients regarding treatment for atopic dermatitis.

TJ Chao breaks down the black box warnings for ruxolitinib cream 1.5% and discusses the importance in communicating the specifics of these warnings to patients.

Mr. Chao discusses the reliability of ruxolitinib cream 1.5% in treating patients with atopic dermatitis. He emphasized how well it is tolerated by patients, as

Dr. Matthew Zirwas reviews atopic dermatitis treatments that have been essential in providing immediate improvement in itch leading to a sense of control in his

Dr. Silverberg discusses how to safely counsel patients when deciding between topical versus oral JAK inhibitors for the treatment of atopic dermatitis.

Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr.